Home » ABBOTT LABS STILL HAS 'CONSIDERABLE' UPSIDE POTENTIAL
ABBOTT LABS STILL HAS 'CONSIDERABLE' UPSIDE POTENTIAL
Banc of America Securities reiterated a "buy" rating on Abbott Laboratories and lowered the target price to $46 from $49. The research firm said "there is still much to like" about Abbott, and that shares of the healthcare-products company have "considerable" upside potential.
Forbes (http://www.forbes.com/2005/11/28/abbott-labs-earnings-1128markets14_print.html)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May